General Policy

IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the framework of comparative physiology and pathology. The special focus of the journal is the publication of works on: (a) experimental development and the application of new diagnostic procedures; (b) pharmacological and toxicological evaluation of new drugs and drug combinations; (c) development and characterization of models for biomedical research.

One of the principal aims of IN VIVO is to provide for the prompt publication of accepted articles, generally within 1-2 months from final acceptance.

IN VIVO supports: (a) the aims and the research programmes of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (IIAR) (Kapandriti, Attiki, Greece) and (b) the organization of the INTERNATIONAL CONFERENCES OF ANTICANCER RESEARCH.

Editorial Office

International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece. Tel and Fax: +30-22950-53389; e-mail: journals@iiar-anticancer.org
For more information about IN VIVO, IIAR and the conferences please visit the IIAR websites: www.iiar-anticancer.org and www.iiarnjournals.org

Selection of Recent Articles

Animal Models of N-Methyl-N-nitrosourea-induced Mammary Cancer and Retinal Degeneration with Special Emphasis on Therapeutic Trials. A. TSUBURA, Y.-C. LAI, H. MIKI, T. SASAKI, N. UEHARA, T. YURI, Y. YOSHIZAWA (Osaka, Japan)


Effects of Combined Insulin-like Growth Factor 1 and Macrophage Colony-stimulating Factor on the Skeletal Properties of Mice. S.A. LLOYD, S.J. SIMSKS, L.K. BOGREN, S.E. OLESIKA, T.A. BATEMAN, V.L. FERGUSON (Hershey, PA; Boulder, Fort Collins, CO; Chapel Hill, NC, USA)

Cell Death Detection after High-LET Irradiation in an Orthotopic Human Hepatocellular Carcinoma in Vivo. A. ALTMEYER, M. IGNAT, J.-M. DENIS, N. MESSADDEQ, J. GUEULETTE, D. MUTTER, P. BISCHOFF (Strasbourg; Illkirch Graffenstaden, France; Brussels, Belgium)

Serum Calcium-decreasing Factor, Caldecrin, Ameliorates Muscular Dystrophy in dj/dj Mice. M. TOMOMURA, T. FUJII, H. SAKAGAMI, A. TOMOMURA (Saitama; Tokushima, Japan)

Nitric Oxide Concentrations are Normal and Unrelated to Activity Level in Chronic Fatigue Syndrome. M. MEEUS, I. VAN EUPEN, J. HONDEQUIN, L. DE HAUWERE, D. KOS, J. NUIS (Antwerpen; Brussels, Belgium)

Gene Expression Analysis of Oxidative Stress and Apoptosis in Proton-irradiated Rat Retina. X.W. MAO, L.M. GREEN, T. MEKONNEN, N. LINDSEY, D.S. GRIDLEY (Loma Linda, CA, USA)

Colon Cancer Vaccines: An Update. E. MERKA, M.W. SAIF, A. KATZ, K. SYRIGOS, M. MORSE (London, UK; Haven, CT; Durham, NC, USA; Athens, Greece)


CD95 and TNFα-induced Apoptosis in Liver Metastases of Colorectal Carcinoma. H.-U. KASPER, E. KONZE, M. KERN, D.L. STIPPEL (Münster; Köln; Heidelberg, Germany)

Thrombogenicity of Sirolimus-eluting Stents and Bare Metal Stents: Evaluation in the Early Phase after Stent Implantation. T. WALTER, K.S. REY, H.P. WENDEL, S. SZABO, T. SUSELBECK, C.-E. DEMPFL, M. BORGREGRE, S. SWOBODA, M.E. BEYER, H.M. HOFFMEISTER (Mannheim; Kürheim; Tuebingen; Solingen, Germany)

Non-antibiotics Reverse Resistance of Bacteria to Antibiotics. J.E. KRISTIANSEN, V.F. THOMSEN, A. MARTINS, M. VIVEIRO, L. AMARAL (Odense; Copenhagen, Denmark; Lisbon, Portugal)


A Possible Mechanism for Altered Immune Response in the Elderly. G. MAZZOCCOLL, A. DE CATA, S. CARUGHI, A. GRECO, M. INGLESE, F. PERFETTO, R. TARQUINI (San Giovanni Rotondo; Florence, Italy)

Urine and Serum Analysis of Consumed Curcuminoids Using an IκB-luciferase Surrogate Marker Assay. S. PONNURANGAM, F.G. MONDALEK, J. GOVIND, D. SUBRAMANIAM, C. HOUCHEN, S. ANANT, P. PANTAZIS, R.P. RAMANUJAM (Oklahoma City, OK, USA)
Instructions to Authors

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide for the prompt publication of original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrantee due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has passed from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without written consent of the Managing Editor.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) short papers. Additionally, the Editors may invite review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the “Shorter Oxford English Dictionary”.

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double-spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:
(a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “clinical”, “epidemiological”, or “experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, glossy prints of the size they are to appear in the journal: 8.00 cm (3.15 in) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated on the reverse side. Original karyotypes and photographs should be provided wherever possible, and not photographic copies. Colour plates are charged.

Tables. Each table should be submitted on a separate page, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

Nomenclature and Abbreviations. Nomenclature should follow that given in “Chemical Abstracts”. Standard abbreviations will be preferable. If a new abbreviation is used, it must be defined at its first usage.

Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text. For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

Submission of Manuscripts. Follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your articles twice):

1. To submit your article online please visit: IIAR-Submissions (http://www.iiar-anticancer.org/submissions/login.php)
2. You can send your article via e-mail to journals@iiar-anticancer.org. Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies of your manuscript to the following address:
   John G. Delinassios
   International Institute of Anticancer Research (IIAR)
   Editorial Office of ANTICANCER RESEARCH,
   IN VIVO, CANCER GENOMICS and PROTEOMICS.
   1st km Kapandritiou-Kalamou Road
   P.O. Box 22, GR-19014 Kapandriti, Attiki
   GREECE

Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors.

Reprints. Twenty-five copies of each communication will be provided free-of-charge. Additional copies or PDF files may be ordered after the acceptance of the paper. Requests for additional reprints should be addressed to the Editorial Office.

Copyright © 2011 - International Institute of Anticancer Research (J.G. Delinassios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.
A Selection of Recent Papers

Meta-data Analysis as a Strategy to Evaluate Individual and Common Features of Proteome Changes in Breast Cancer. O. ZAKHARCHENKO, C. GREENWOOD, A. LEWANDOWSKA, U. HELLMAN, L. ALLDRIDGE, S. SOUCHELNYTSKYI (Stockholm; Uppsala, Sweden; Chelmsford, UK; Olsztyn, Poland; Gold Coast, QLD, Australia)

Circadian Transcription Profile of Mouse Breast Cancer under LD and DD Conditions. E.-Y. OH, X. YANG, A. FRIEDMAN, C.M. ANSELL, J. DUQUOTON, D.F. QUITON, P.A. WOOD, W.J.M. HRUSHESKY (Columbia, SC; St. Louis, MO, USA)

Interleukin 6/Interleukin 6 Receptor Interaction and its Role as a Therapeutic Target for Treatment of Cachexia and Cancer. U.H. WEIDLE, S. KLOSTERMANN, D. EGGLE, A. KRÜGER (Munich, Germany)

A Biotin Label-based Antibody Array for High-content Profiling of Protein Expression. R. HUANG, W. JIANG, J. YANG, Y.Q. MAO, Y. ZHANG, W. YANG, D. YANG, B. BURKHOLDER, R.F. HUANG, R.-P. HUANG (Norcross, GA, USA; Guangzhou, P.R. China)

TGF-β1 Interactome: Metastasis and Beyond. M. PERERA, C.S. TSANG, R.J. DISTEL, J.N. LACY, L. OHNO-MACHADO, V. RICCHIUTI, L.P. SAMARANAYAKE, G.B. SMEJKAI, M.G. SMITH, A.J. TRACHTENBERG, W.P. KUO (Hong Kong, Hong Kong; Boston, MA, USA)

Epigenetic Inactivation of the Placentally Imprinted Tumor Suppressor Gene TFPI2 in Prostate Carcinoma. T. RIBARSKA, M. INGENWERTH, W. GOERING, R. ENGERS, W.A. SCHULZ (Düsseldorf, Germany)

Proteomic Study of Sera from Patients with Bladder Cancer: Usefulness of S100A8 and S100A9 Proteins. S. MINAMI, Y. SATO, T. MATSUMOTO, T. KAGEYAMA, Y. KAWASHIMA, K. YOSHIO, J.-I. ISHI, K. MATSUMOTO, R. NAGASHIO, I. OKAYASU (Kanagawa, Japan)

Analysis of Protein Phosphorylation in Cisplatin-treated Human Cells Following Annexin V-based Separation and Multi-Antibody Screening. E. O’MEARA, S. CRUET-HENNEQUART, M.P. CARTY (Galway, Ireland)


DNA-based Assay for EPHB6 Expression in Breast Carcinoma Cells as a Potential Diagnostic Test for Detecting Tumor Cells in Circulation. B.P. FOX, R.P. KANDPAL (Pomona, CA, USA)

Discovery of Serum Protein Biomarkers for Prostate Cancer Progression by Proteomic Analysis. J.A. ALRUWAILI, S.E. T. LARKIN, B.A. ZEIDAN, M.G. TAYLOR, C.N. ADRA, C.L. AUKIM-HASTIE, P.A. TOWNSEND (Hampshire, UK; Riyadh, Kingdom of Saudi Arabia; Boston, MA, USA)

Use of NG2 (7.1) in AML as a Tumor Marker and its Association with a Poor Prognosis. K. PETROVICI, M. GRAF, K. HECHT, S. REIF, K. PFISTER, H. SCHMETZER (Regensburg; Munich, Germany)
Subscription Order Form 2011

☐ Please enter a Subscription to ANTICANCER RESEARCH for Volume 31 (2011).

Annual subscription rates (2011): Institutional, Euro 1,650.00 - online; 1,670.00 - print; 1,700.00 - print & online.
Personal, Euro 780.00 - online; 800.00 - print; 830.00 - print & online. Prices include rapid delivery and insurance.

☐ Please send me the following previous volumes (1-30) at 50% discount on the above rates:

☐ Payment is enclosed.  ☐ Please invoice.

(Cheques should be made payable to J.G. Delinassios, Athens, Greece)

☐ Please send me information about the International Institute of Anticancer Research (IIAR).

Name and Address: .................................................................................................................................................................

Tel: ...............................................................................................................................................................................................

Fax: ...............................................................................................................................................................................................

Signature:..................................................................................................................................................................................

Date:....................................................................................................................................................................................

Please send this order to ANTICANCER RESEARCH, Editorial Office, IIAR, 1st km Kapandriou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece. Tel & Fax: +30-22950-53389, e-mail: journals@iiar-anticancer.org

Special 2011 Offers to Authors of ANTICANCER RESEARCH

(These offers are open to all authors of articles published in Anticancer Research from 1981-2011 on a basis of priority and availability. Effective from January to December 2011).

Please complete and send this order form to:
ANTICANCER RESEARCH Editorial Office, International Institute of Anticancer Research,
1st km Kapandriou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece.

Special Subscription Order Form 2011

☐ I am one of the authors of the article published in Anticancer Research Vol........, pp. ..........., year ........

☐ Please enter my personal subscription to Anticancer Research 2011 (Volume 31) at the special Author’s rate of Euro 417.00 (print or online); Euro 500.00 (print & online).

☐ Please send me previous Volume No(s) ............ at Euro 208.00 per volume.

☐ Please enter my personal combined 2011 subscription to Anticancer Research (Volume 31), IN VIVO (Volume 25) and CANCER GENOMICS & PROTEOMICS (Volume 8) at Euro 755.00 (print or online); Euro 972.00 (print & online).

☐ My payment is enclosed.

☐ Please send me an invoice.

(Prices include rapid delivery and insurance. Cheques should be made payable to J.G. Delinassios, Athens, Greece).

Name and address: .................................................................................................................................................................

Tel-Fax: ...............................................................................................................................................................................................

E-mail: ...............................................................................................................................................................................................

Date and signature: ........................................................................................................................................................................

Sifneos Alexithymia Questionnaire in Assessment of General Alexithymia in Patients with Breast Disease and Breast Cancer: A Prospective Case–Control Study in Finland. M. ESKELINEN, P. OLLONEN (Kuopio, Finland) .................................................................................................................................................. 3101

The Role of MonoTotal in the Primary Diagnosis, Prognosis and Follow-up of Patients with Non-small Cell Lung Cancer (NSCLC). M. PRAZAKOVA, J. VRZALOVA, J.M. AUGE, J. SAFRANEK, O. TOPOLCAN, R. FUCHSOVA, M. SPISAKOVA, S.SVOBODOVA, L. HOLUBEC JR., M. PESTA (Prague; Pilsen, Czech Republic; Barcelona, Spain) ........................................................................................................... 3107

Erratum ........................................................................................................................................................................... 3113

* Review (page 2923)
Differential Activation of MAPK and PI3K/AKT/mTOR Pathways and IGF1R Expression in Gastrointestinal Stromal Tumors. M.J. RÍOS-MORENO, S. JARAMILLO, M. DÍAZ-DELGADO, M. SÁNCHEZ-LEÓN, I. TRIGO-SÁNCHEZ, J. POLO PADILLO, J. AMÉRIGO, R. GONZÁLEZ-CÁMPORA (Seville; Badajoz; Almeria, Spain) .................................................. 3019

Correlation of Intensity of MT-I/II Expression with Ki-67 and MCM-2 Proteins in Invasive Ductal Breast Carcinoma. A. WOJNAR, B. PULA, A. PIOTROWSKA, A. JETHON, K. KUJAWA, C. KOBIERZYCKI, J. RYS, M. PODHORSKA-OKOLOW, P. DZIEGIEL (Wrocław; Poznan; Krakow, Poland) ........................................ 3027

Phase I Study of S-1 in Combination with Trastuzumab for HER2-positive Metastatic Breast Cancer. T. NAKAYAMA, S. MORITA, T. TAKASHIMA, S. KAMIGAKI, K. YOSHIDOME, T. ITO, T. TAGUCHI, J. SAKAMOTO, S. NOGUCHI (Osaka; Kanagawa; Nagoya, Aichi, Japan) .................................................. 3035


Fertility-sparing Management of Grade 2 and 3 Endometrial Adenocarcinomas. M. KOSKAS, C. YAZBECK, F. WALKER, E. CLOUQUEUR, A. AGOSTINI, S. RUAT, J.P. LUCOT, E. LAMBAUDIE, D. LUTON, P. MADELEMET (Paris; Lille; Marseille, France) ........................................ 3047

Effect of Glutathione-S-Transferase M1 and T1 Allelic Polymorphisms on HPV-induced Cervical Precancer Formation. J. CSEH, E. PÁZSIT, Z. ORSÓS, E. MAREK, A. HUSZÁR, S. BALOGH, I. EMBER, I. KISS (Székesfehérvár; Miskolc; Pécs; Budapest, Hungary) ........................................ 3051

Gene Polymorphisms MTHFR C677T and A2756G as Predictive Factors in Adjuvant Chemotherapy for Stage III Colorectal Cancer. H. TAFLIN, Y. WETTERGREN, E. ODIN, G. CARLSSON, K. DERWINGER (Gothenburg, Sweden) ........................................ 3057

Evaluation of Oral Etoposide in Combination with Cisplatin for Patients with Recurrent Cervical Cancer: Long-term Follow-up Results of a Japanese Multicenter Study. Y. WATANABE, H. HOSHIAI, T. NAKANISHI, N. KAWAMURA, N. TANAKA, K. ISAKA, S. KAMURA, M. OHMACHI, M. HATAE, K. OCHIAI (Osaka; Nagoya; Chiba; Tokyo; Kagoshima, Japan) ........................................ 3063


Neoadjuvant Chemoradiotherapy for Clinical Stage II-III Esophageal Squamous Cell Carcinoma. H. SAeki, M. MORITA, Y. NAKASHIMA, H. SONODA, K. HASHimoto, A. EGASHira, E. OKI, T. OHGA, Y. KAKEJI, Y. MAEHARA (Fukuoka, Japan) ........................................ 3073

Phase I Study of Neoadjuvant Chemoradiotherapy Consisting of S-1 and Cisplatin for Patients with Resectable Advanced Gastric Cancer (KOGC-01). T. TAKAHASHI, Y. SAIKAWA, H. TAKAISHI, H. TAKEUCHI, N. WADA, T. OYAMA, K. FUKUDA, J. FUKADA, O. KAWAGUCHI, N. SHIGEMATSU, Y. KITAGAWA (Tokyo, Japan) ........................................ 3079

Feasibility Study of Triplet Combination Chemotherapy of Paclitaxel, Cisplatin and S-1 for Advanced Gastric Cancer. K. FUJITANI, H. HASEGAWA, M. HIRAO, Y. KUROKAWA, T. TSUJINAKA (Osaka, Japan) ........................................ 3081
<table>
<thead>
<tr>
<th>Title</th>
<th>Authors</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nonhepatic Cancer in Liver Cirrhosis: A Retrospective Study of Prevalence, Complication Rate after Specific Oncological Treatment, Follow-up and Prognostic Predictors of Outcome in 354 Patients with Cirrhosis.</td>
<td>F. GUNDLING, H. SEIDL, F. SCHMIDTLER, N. LÖFFLER, I. STRASSEN, P. WOLF, C. PEHL, T. SCHMIDT, W. SCHEPP (Munich; Vilsbiburg, Germany)</td>
<td>2931</td>
</tr>
<tr>
<td>Basic Clinical Parameters Predict Gefitinib Efficacy in Non-small Cell Lung Cancer.</td>
<td>A. PIRCHER, E. ULSPERGER, R. HACK, H. JAMNIG, G. PALL, B. ZELGER, W. STERLACCI, W. HILBE, M. FIEGL (Innsbruck; Tyrol; Feldkirch, Austria)</td>
<td>2949</td>
</tr>
<tr>
<td>Palladin is a Marker of Liver Metastasis in Primary Pancreatic Endocrine Carcinomas.</td>
<td>E.B. HENDERSON-JACKSON, J. HELM, J. STROSBERG, N.A. NASIR, T.J. YEATMAN, L.K. KVOLS, D. COPPOLA, A. NASIR (Tampa, FL, USA)</td>
<td>2957</td>
</tr>
<tr>
<td>Elevated YB-1 Expression is a New Unfavorable Prognostic Factor in Non-Hodgkin’s Lymphomas.</td>
<td>K. SZCZURASZEK, A. HALON, V. MATERNA, G. MAZUR, T. WROBEL, K. KULICZKOWSKI, P. DONIZY, P.S. HOLM, H. LAGE, P. SUROWIAK (Wrocław, Poland; Berlin; Munich, Germany)</td>
<td>2963</td>
</tr>
<tr>
<td>RASSF1A Methylation is Predictive of Poor Prognosis in Female Breast Cancer in a Background of Overall Low Methylation Frequency.</td>
<td>A. BÜHMEIDA, A. MERDAD, J. EL-MAGHRABI, F. AL-THOBAITI, M. ATA, A. BUGIS, K. SYRJÄNEN, A. ABUZENADAH, A. CHAUDHARY, M. GARI, M. AL-QAHTANI, A. DALLOL (Jeddah, Saudi Arabia; Turku, Finland)</td>
<td>2975</td>
</tr>
<tr>
<td>A Low-grade Myofibroblastic Sarcoma in the Abdominal Cavity.</td>
<td>M. MIYAZAWA, Y. NARIITAKA, A. MIYAKI, S. ASAKA, N. ISOHATA, K. YAMAGUCHI, M. MURAYAMA, T. SHIMAKAWA, T. KATSUBE, K. OGAWA, M. FUJIBAYASHI (Tokyo, Japan)</td>
<td>2989</td>
</tr>
<tr>
<td>Preoperative Neutrophil to Lymphocyte Ratio as a Prognostic Predictor after Curative Resection for Non-small Cell Lung Cancer.</td>
<td>M. TOMITA, T. SHIMIZU, T. AYABE, A. YONEI, T. ONITSUKA (Miyazaki, Japan)</td>
<td>2995</td>
</tr>
</tbody>
</table>


Determination of Clofarabine Triphosphate Concentrations in Leukemia Cells Using Sensitive, Isocratic High-performance Liquid Chromatography. T. YAMAUCHI, R. NISHI, T. UEDA (Fukuoka, Japan) ............. 2863

H-ras Up-regulates Expression of BNIP3. W. KALAS, E. SWIDEREK, A. RAPAK, M. KOPIJ, J. RAK, L. STRZADALA (Wroclaw, Poland; Montreal, QC, Canada) ................................................................. 2869


Prediction of Synergistic Antitumour Effect of Gefitinib and Radiation In Vitro. H.Q. LIN, H. MERYATY, A. KATSIFIS (Lucas Heights, NSW, Australia) ................................................................. 2883


Etodolac Improves 5-FU Sensitivity of Head and Neck Cancer Cells through Inhibition of Thymidylate Synthase. S. MURATA, M. ADACHI, M. KIOI, S. TORIGOE, K. IIICHII, Y. HASEGAWA, T. OGAWA, M.K. BHAYAN, S.Y. LAI, K. MITSUDO, I. TOHNAY (Yokohama; Nagoya; Nagakute, Aichi, Japan; Houston, TX, USA) ................................................................. 2893

Down-regulation of Expression of Interleukin-6 and its Receptor Results in Growth Inhibition of MCF-7 Breast Cancer Cells. X.-P. JIANG, D.C. YANG, R.L. ELLIOTT, J.F. HEAD (Baton Rouge, LA, USA) ................................................................. 2899

Comparison of μCT, MRI and Optical Reflectance Imaging for Assessing the Growth of GFP/RFP-expressing Tumors. L. ABOU-ELKACEM, F. GREMSE, S. BARTH, R.M. HOFFMAN, F. KIESSLING, W. LEDERLE (Aachen, Germany; San Francisco; San Diego, CA, USA) ................................................................. 2907

Panipenem Does Not Alter the Pharmacokinetics of the Active Metabolite of Irinotecan SN-38 and Inactive Metabolite SN-38 Glucuronide (SN-38G) in Rats. A. KATO, J. UEYAMA, F. ABE, K. HOTTAY, I. TSUKIYAMA, T. OSHIMA, F. KONDO, H. SAIITO, T. HASEGAWA (Aichi-gun; Nagoya; Aichi; Kanazawa, Ishikawa, Japan) ................................................................. 2915

Clinical Studies

* Review: CT and MR Imaging of the Adrenal Glands in Cortisol-secreting Tumors. F. LUMACHI, P. MARCHESI, D. MIOTTO, R. MOTTA (Padova, Italy) ................................................................. 2923

Cryotreatment against Metastatic Renal Cell Bone Tumour Reduced Multiple Lung Metastases. H. NISHIDA, T. SHIRAI, K. HAYASHI, A. TAKEUCHI, Y. TANZAWA, A. MIZOKAMI, M. NAMIKI, H. TSUCHIYA (Kanazawa, Japan) ................................................................. 2927

Contents continued on the preceding page
Protein-bound Polysaccharide-K (PSK) Induces Apoptosis and Inhibits Proliferation of Promyelomonocytic Leukemia HL-60 Cells. N. HIRAHARA, M. FUJIOKA, T. EDAMATSU, A. FUJIEDA, F. SEKINE, T. WADA, T. TANAKA (Izumo; Tokyo, Japan) ................................................................. 2733

Clioquinol Suppresses Cyclin D1 Gene Expression through Transcriptional and Post-transcriptional Mechanisms. J. ZHENG, D.M. BENBROOK, H. YU, W.-Q. DING (Oklahoma City, OK, USA; Wuhhan, PR China) ................................................................. 2739

Prognostic Relevance of Disseminated Tumor Cells in the Bone Marrow of Patients with Primary Breast Cancer – Results of a Standardized Follow-Up. C. SCHINDLBECK, G. PFAB, J. JUECKSTOCK, U. ANDERGASSEN, H. SOMMER, W. JANNI, K. FRIESE, B. RACK (Traunstein; Munich; Duesseldorf, Germany) ................................................................. 2749

Modulation of Cisplatin Cytotoxicity due to its Combination with Bortezomib and the Nature of its Administration. Z. AL-EISAWI, P. BEALE, C. CHAN, J.Q. YU, F. HUQ (Sydney, NSW, Australia) ........ 2757

Prognostic Significance of Thymidylate Synthase Expression in the Adjuvant Chemotherapy after Resection for Pulmonary Metastases from Colorectal Cancer. K. KAIRA, T. OKUMURA, Y. OHDE, T. TAKAHASHI, H. MURAKAMI, H. KONDO, T. NAKAJIMA, N. YAMAMOTO (Shizuoka, Japan) ................................................................. 2763

In Vitro and In Vivo Anticancer Activity of (+)-Spongistatin 1. Q. XU, K.-C. HUANG, K. TENDYKE, J. MARSH, J. LIU, D. QIU, B.A. LITTLEFIELD, K. NOMOTO, O. ATASOYLU, C.A. RISATTI, J.B. SPERRY, A.B. SMITH III (Andover, MA; Philadelphia, PA, USA) ................................................................. 2773

Interaction of Dacarbazine and Imexon, In Vitro and In Vivo, in Human A375 Melanoma Cells. B.K. SAMULITIS, R.T. DORR, H.-H.S. CHOW (Tucson, AZ, USA) ................................................................. 2781


SDF1β Expression in Renal Cell Carcinoma Correlates with Grading and Infiltration by CD8+ T-Cells. T.C. WEHLER, C. GRAF, K. ALTHERR, T. ZIMMERMANN, W. BRENNER, J.W. THÜOFF, S. BIESTERFELD, I. GOCKEL, M. THEOBALD, P.R. GALLE, C.C. SCHIMANSKI (Mainz; Duesseldorf, Germany) ................................................................. 2797

Activation of the Wnt/Beta-catenin Signaling Pathway during Oral Carcinogenesis Process Is Not Influenced by the Absence of Galectin-3 in Mice. J.M. SANT’ANA, R. CHAMMAS, F.-T. LIU, S. NONOGAKI, S.V. CARDOSO, A.M. LOYOLA, P.R. DE FARIA (Uberlândia; São Paulo, Brazil; Sacramento, CA, USA) .......... 2805

Anti-MDR1 siRNA Restores Chemosensitivity in Chemoresistant Breast Carcinoma and Osteosarcoma Cell Lines. J. PEREZ, C. BARDIN, C. RIGAL, B. ANTHONY, R. ROUSSEAU, A. DUTOIR (Lyon; Villeurbanne, France) ................................................................. 2813


Correlation between Expression of Metallothionein and Expression of Ki-67 and MCM-2 Proliferation Markers in Non-small Cell Lung Cancer. B. WERYNSKA, B. PULA, B. MUSZCZYNSKA-BERNHARD, A. PIOTROWSKA, A. JETHON, M. PODHORSKA-OKOLOW, P. DZIEGIEL, R. JANKOWSKA (Wroclaw; Poznan, Poland) ................................................................. 2833